Cagrilintide for Weight Loss

Cagrilintide/semaglutide, marketed as CagriSema, is a combination of cagrilintide, a dual amylin and calcitonin receptor agonist, and semaglutide, a GLP-1 agonist. It is being tested in type 2 diabetes and obesity. These separate, but related mechanisms of action of an amylin-analog and a GLP-1 receptor agonist appear to have an additive effect on appetite reduction. The combination of cagrilintide and semaglutide has shown good tolerability in clinical trials, has a weight loss effect, and can achieve sustained weight management.